Sionna Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Sionna Therapeutics is developing next-generation small molecule CFTR modulators targeting full restoration of CFTR protein function in cystic fibrosis patients; raised $170M+ total;
About
Sionna Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Lexington, Massachusetts. The company was founded with a focus on discovering and developing next-generation treatments for cystic fibrosis (CF) — a life-threatening genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that impair the protein's ability to regulate fluid transport in the lungs, digestive tract, and other organs. While Vertex Pharmaceuticals' Trikafta has transformed CF treatment for patients with the most common mutation (F508del), Sionna aims to develop modulators that more fully restore CFTR function and address patient segments not adequately covered by existing drugs.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.